Portal de Periódicos da CAPES

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

2018; Springer Nature; Volume: 119; Issue: 2 Linguagem: Inglês

10.1038/s41416-018-0131-9

1532-1827

Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Ravit Geva, Hyun Cheol Chung, Chia‐Chi Lin, Deepti Aurora-Garg, Archana Ray, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow, Robert I. Haddad,

Head and Neck Cancer Studies

Second-line treatment options for advanced head and neck squamous cell carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the efficacy of pembrolizumab for the treatment of HNSCC after long-term follow-up.